BU researchers uncover links between metabolism and aggressive breast cancer
Peer-Reviewed Publication
Updates every hour. Last Updated: 5-Jul-2025 04:10 ET (5-Jul-2025 08:10 GMT/UTC)
More than 120 million Americans suffer from diabetes or pre-diabetes. Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer, and TNBC patients with obesity-driven diabetes often have worse outcomes.
A new study by researchers from Boston University Chobanian & Avedisian School of Medicine helps explain why this happens and suggests a potential way to improve treatment for these patients.
The researchers' new method, called chemical tomography, provides insights into tissue function by analyzing volatile organic compounds (VOCs). These molecules are present in exhaled breath, saliva, sweat, and other bodily fluids. Prof. Haick is a leading global expert in the use of VOCs for early disease detection. His prior research has led to the development of multiple diagnostic technologies based on VOC analysis.
In this study, VOC monitoring enabled the dynamic molecular and functional mapping of a human breast tissue organoid, revealing key protein and genomic data associated with the transformation of healthy breast tissue into cancerous tissue.
The system detects VOCs using a graphene-based sensor array, with the collected data analyzed through generative artificial intelligence (AI). The inspiration for this technology comes from the compound eye of insects – a structure composed of multiple small eyes that send numerous images to the insect’s brain for analysis. In the system, the graphene sensors function as the compound eye, while AI acts as the brain, processing and interpreting the data.
BRCA1 and BRCA2 genes play a crucial role in repairing damaged DNA. Mutations in BRCA1 and BRCA2 substantially increase the likelihood of breast and ovarian cancer, respectively. This new research illustrates how small breaks in one strand of DNA can expand into a large single-stranded DNA gap that kills drug-resistant breast BRCA mutant cancer cells. The novel vulnerability in mutant BRCA1 and BRCA2 may be a potential target for new therapeutics.
Cancer and cardiovascular diseases (CVDs) share common risk factors, and treatments for cancer have the potential to increase the risk of CVDs. Researchers have elaborated on the importance of recognizing the indicators, patterns, predictive outcomes, and challenges associated with CVD risks in cancer patients and survivors. Proactive management and early detection are essential to improving the overall health outcomes and quality of life for patients with cancer.
Researchers from SRM Institute of Science and Technology, led by Dr. KN Aruljothi, have published a study in ExRNA highlighting the role of exosomal RNA (exRNA) in head and neck cancers (HNCs). Exosomal RNAs, including miRNA, mRNA, and lncRNA, are secreted by tumor cells and play a pivotal role in cancer progression by modulating key signaling pathways such as NF-κB, EGFR, and PI3K/AKT/mTOR. These exRNAs influence the tumor microenvironment, promote metastasis, and contribute to immune evasion and therapy resistance. The study underscores the potential of exRNA-based liquid biopsy through saliva and blood samples for early diagnosis and treatment monitoring, presenting a promising avenue for precision oncology in HNC management.
Cancer treatment has advanced significantly, focusing on targeted approaches that destroy tumor cells while sparing healthy tissue. Researchers at JAIST have developed magnetic nanoparticles that can be directed to tumors using a magnet and then heated with a laser to destroy cancer cells. In mouse models, this targeted technique successfully eliminated tumors entirely. This innovative method provides a more precise and less toxic alternative to traditional treatments, paving the way for more effective cancer therapies.
A new paper in the Journal of Breast Imaging indicates that breast cancer mortality rates have stopped declining in women older than age 74, and reconfirms that breast cancer mortality rates have stopped falling in women younger than age 40. This finding for older women is new.
New research shows that a common type of diabetes medication could help cancer patients make a better long-term recovery. Many cancer patients go on to develop heart failure - because of the cancer itself and also due to chemotherapy.
But a new study shows that a type of diabetes drug, called an SGLT2 inhibitor, may help protect the heart during and after cancer treatment.
This is the first time that any medication has been shown to be beneficial in reducing heart failure or heart failure hospitalisation in cancer patients and survivors.
Cancer cells have an insatiable appetite for energy as they multiply more rapidly than normal cells. Greedy cancer cells hijack various cellular functions to find and exploit energy and other resources, including a group of enzymes that help normal cells maintain a balance of energy.
These enzymes, called creatine kinases (CK), allow cells to transport energy produced at the mitochondria to where it is needed throughout the cell. Studies of breast cancer cells have highlighted the importance of a type of CK called ubiquitous mitochondrial creatine kinase (uMtCK).
New research published in Structure will serve as the foundation for a collaborative team of Sanford Burnham Prebys and Mayo Clinic investigators to design and develop novel small molecules that selectively inhibit uMtCK to treat breast cancer.